Compass Therapeutics, Inc.

AI-generated fair value estimate for this company.

Method: Going-concern-adjusted net cash value: $170.25M net cash ($0.95/share on 180.09M shares) haircut to 70% to reflect roughly 2-3 years of runway at the current ~$56M annual operating cash burn, plus a $0.40/share risk-adjusted option value for the ozuriftamab vedotin (CTX-009) biliary tract cancer program following positive Phase 2 interim data.

Reasoning: Compass Therapeutics is a clinical-stage oncology biotech trading near its net cash value with no approved products, so the most reliable estimate of intrinsic value is a burn-adjusted net cash floor plus a modest, explicitly risk-adjusted allowance for the one clinical program (CTX-009) that has shown positive interim efficacy data and partnership potential.